Ocular Therapeutix, Inc.
OCUL
$11.37
$0.121.02%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 55.78M | 56.66M | 59.65M | 63.72M | 61.44M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 55.78M | 56.66M | 59.65M | 63.72M | 61.44M |
| Cost of Revenue | 193.50M | 177.98M | 155.32M | 133.26M | 108.62M |
| Gross Profit | -137.71M | -121.31M | -95.67M | -69.54M | -47.18M |
| SG&A Expenses | 126.22M | 119.92M | 112.81M | 106.64M | 85.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 319.72M | 297.90M | 268.13M | 239.90M | 194.00M |
| Operating Income | -263.93M | -241.23M | -208.48M | -176.18M | -132.56M |
| Income Before Tax | -249.67M | -216.75M | -192.71M | -193.51M | -174.34M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -249.67 | -216.75 | -192.71 | -193.51 | -174.34 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -249.67M | -216.75M | -192.71M | -193.51M | -174.34M |
| EBIT | -263.93M | -241.23M | -208.48M | -176.18M | -132.56M |
| EBITDA | -259.91M | -237.32M | -204.64M | -172.40M | -128.76M |
| EPS Basic | -1.44 | -1.28 | -1.15 | -1.26 | -1.32 |
| Normalized Basic EPS | -0.95 | -0.85 | -0.73 | -0.67 | -0.66 |
| EPS Diluted | -1.44 | -1.28 | -1.15 | -1.26 | -1.32 |
| Normalized Diluted EPS | -0.95 | -0.85 | -0.73 | -0.67 | -0.66 |
| Average Basic Shares Outstanding | 693.93M | 677.00M | 670.23M | 632.86M | 549.27M |
| Average Diluted Shares Outstanding | 693.93M | 677.00M | 670.23M | 632.86M | 549.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |